Page 9 - Exact Sciences News Today

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report)’s stock price rose 7.3% during mid-day trading on Thursday . The stock traded as high as $60.52 and last traded at $60.35. Approximately 1,181,042 shares changed hands during mid-day trading, a decline of 40% from the average daily volume of 1,954,303 shares. The stock had previously closed […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) CEO Kevin T. Conroy sold 6,263 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $56.89, for a total transaction of $356,302.07. Following the completion of the sale, the chief executive officer now directly owns […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) CFO Jeffrey Thomas Elliott sold 2,710 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $56.89, for a total value of $154,171.90. Following the transaction, the chief financial officer now owns 8,054 shares of the […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) EVP Sarah Condella sold 1,880 shares of Exact Sciences stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $56.89, for a total value of $106,953.20. Following the completion of the transaction, the executive vice president now directly owns 73,732 […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) EVP Sarah Condella sold 1,021 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $59.72, for a total value of $60,974.12. Following the transaction, the executive vice president now owns 71,658 shares of the company’s stock, […]

The test, using blood or saliva, can evaluate genetic risk for colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine cancers.

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) insider Jacob A. Orville sold 1,879 shares of the company’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $56.89, for a total value of $106,896.31. Following the sale, the insider now owns 11,754 shares of the company’s stock, […]

MADISON, Wis. -- There is a start-up silently saving jobs – and lives - here in Madison, and you might not even know about it.

Phase 2 EDA Tech Hub Funding Application Fueled by Collaboration...

The test, using blood or saliva, can evaluate genetic risk for colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine cancers.